More News

9 May 2023

Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck

4 May 2023

Sandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines

2 May 2023

Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease

1 May 2023

Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

27 April 2023

ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer

25 April 2023

4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy

21 April 2023

Oncoinvent Announces Two Publications in Special Edition of Frontiers in Medicine Focused on Alpha Radioisotopes

18 April 2023

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics

18 April 2023

GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

17 April 2023

Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

17 April 2023

Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.

13 April 2023

Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity

13 April 2023

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

12 April 2023

Treventis Partners its Preclinical Program in Alzheimer’s Disease with Takeda

5 April 2023

Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets

5 April 2023

Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer

4 April 2023

JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoⓇ for Neurodegenerative Disease

30 March 2023

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

29 March 2023

Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients

28 March 2023

Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates

28 March 2023

Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases

28 March 2023

Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

27 March 2023

Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

23 March 2023

Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines

21 March 2023

CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs

21 March 2023

Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

13 March 2023

Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

13 March 2023

Pfizer Invests $43 Billion to Battle Cancer

8 March 2023

Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline

5 March 2023

Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

5T4-Targeted Immunotherapy Candidates Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

B7-H4 Targeted Antibody Therapy Pipeline Review

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

EpCAM-Targeted Antibodies Pipeline Review